Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
1851
¥ million (net loss)Wording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ending July 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales0 million yen
Operating profit-1,998 million yen
Ordinary income-1,879 million yen
Net income-1,851 million yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
No business revenue, research and development expenses of ¥1,499 million, total business expenses of ¥1,998 million
New initiatives
- Progress in cell manufacturing and preclinical studies for SR-GT1
- Preliminary results update for the additional Phase 2 study of Redasemtide in epidermolysis bullosa
- Out-licensing activities for TRIM3 and TRIM4 to domestic and overseas companies
- Website renewal and communications through X
Key KPIsA metric the company considers important as a management benchmark.
- Annual research and development expenses¥14.9 100 million
- Cash burn rate¥1.34 100 million/month
- Cash and deposits¥53 100 million
- Pipelines with clinical development underway5 bottles
- Number of patents registered11 Engagements
Financial targets
Equity ratio of 70.3% (as of the end of July 2026)Market Size / Share
Includes the market sizes and other information for target diseases in the United States. Examples: 32.5 million people with knee osteoarthritis, 690,000 with acute ischemic stroke, and 5.5 million with cirrhosis.Number of employees
Number of Employees70 people
As ofEnd of July 2026
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ending July 2026 |
| Net Sales | 0 million yen |
| Operating profit | -1,998 million yen |
| Ordinary income | -1,879 million yen |
| Net income | -1,851 million yen |
| Breakdown of Factors Affecting the Change | No business revenue, research and development expenses of ¥1,499 million, total business expenses of ¥1,998 million |
| Key KPIs | Indicator name Annual research and development expenses / Value ¥14.9 100 million / Year on year against the same period last year Not disclosed, Indicator name Cash burn rate / Value ¥1.34 100 million/month / Year on year against the same period last year Not disclosed, Indicator name Cash and deposits / Value ¥53 100 million / Year on year against the same period last year Not disclosed, Indicator name Pipelines with clinical development underway / Value 5 bottles / Year on year against the same period last year Not disclosed, Indicator name Number of patents registered / Value 11 Engagements / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 70 people / As of End of July 2026 |
| Financial targets | Equity ratio of 70.3% (as of the end of July 2026) |
| Market Size / Share | Includes the market sizes and other information for target diseases in the United States. Examples: 32.5 million people with knee osteoarthritis, 690,000 with acute ischemic stroke, and 5.5 million with cirrhosis. |
| New initiatives | Progress in cell manufacturing and preclinical studies for SR-GT1, Preliminary results update for the additional Phase 2 study of Redasemtide in epidermolysis bullosa, Out-licensing activities for TRIM3 and TRIM4 to domestic and overseas companies, Website renewal and communications through X |
Items this document does not state (19)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explained that, given its business model as a drug-discovery biotechnology venture, its revenue structure is unstable. For the fiscal year ended July 2026, it recorded no milestone revenue related to research progress or contract upfront payment revenue, and therefore generated no business revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.